Market Place
Sourcing Support
Fruquintinib Becomes First Antineoplastic Drug to Be Prescribed in US
17 Nov 2023 //
YICAIGLOBAL
Chi-Med Highlights Surufatinib PhIII Results At ESMO & The Lancet
21 Sep 2020 //
GLOBENEWSWIRE
Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib
04 Sep 2020 //
CHI-MED
FDA grants fast track status to Chi-Med’s fruquintinib for colorectal cancer
20 Jun 2020 //
PHARMABIZ
Chi-Med & BeiGene Enter into Clinical Collab to Evaluate Combinations
26 May 2020 //
GLOBENEWSWIRE
Chi-Med Announces that Surufatinib Phase III SANET-p Study Achieved Endpoint
20 Jan 2020 //
BIO SPACE
Chi-Med’s NDA for Surufatinib in Neuroendocrine Tumors Granted Priority Review
20 Dec 2019 //
PRESS RELEASE
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation
25 Nov 2019 //
BIO SPACE
Chi-Med highlights publication of Phase II data for Savolitinib
18 Oct 2019 //
BIOSPACE
Chi-Med’s Surufatinib Study Meets Primary Endpoint Early
03 Jul 2019 //
CONTRACT PHARMA
Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering
03 Jul 2019 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.